ArticleDrugs2012
Phentermine and topiramate extended release (Qsymia™): first global approval.
Article in Drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 35 citations in OpenAlex.
- International consensus on adolescent metabolic health: prevention of obesity and type 2 diabetes.Diabetology & metabolic syndrome · 2026Review
- Topiramate Enhances GABAergic Tone to Orexigenic Neuropeptide Y/Agouti-Related Peptide (NPY/AgRP) Neurons.Obesity (Silver Spring, Md.) · 2026Article
- Obesity Epidemic and Its Impact on Female Fertility: Current Understanding and Future Directions.Cureus · 2025Review
- Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review.Reproductive biology and endocrinology : RB&E · 2025Review
- The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.JCI insight · 2023Article
- Leaf Extract ofNutrients · 2023Article
- Preparation and evaluation of bilayer-core osmotic pump tablets contained topiramate.PloS one · 2022Article
- Successful Treatment of Binge Eating Disorder With Combination Phentermine/Topiramate Extended Release.The primary care companion for CNS disorders · 2015Article
- Treating epilepsy in the setting of medical comorbidities.Current treatment options in neurology · 2014Article
- New pharmacological treatments for the management of obesity.Current gastroenterology reports · 2014Review
- Article
- Phentermine and topiramate for the management of obesity: a review.Drug design, development and therapy · 2013Review
- Self-regulation, motivation, and psychosocial factors in weight management.Journal of obesity · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed to produce weight loss by decreasing appetite and increasing satiety. The product is also in clinical development for sleep apnoea syndrome and type 2 diabetes mellitus. This article summarizes the milestones in the development of phentermine/topiramate ER leading to this first approval for obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.